Abstracts tagged "Biologicals"

Abstract Number: 1389 • ACR Convergence 2024
Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter
Amy Peeters¹, Maike Wientjes², Wieland Müskens¹, David Ten Cate³, Bart van den Bemt⁴, Noortje van Herwaarden¹ and Alfons den Broeder², ¹Sint maartenskliniek, Nijmegen, Netherlands, ²Sint Maartenskliniek, Ubbergen, Netherlands, ³Sint Maartenskliniek, Rotterdam, Netherlands, ⁴Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands
Background/Purpose: Since the compound patent on the bio-originator of adalimumab expired, several adalimumab biosimilars (BS) have been introduced. Extensive research shows equivalence in effectiveness and…
Abstract Number: 1527 • ACR Convergence 2024
Comparative Harms in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab or Belimumab: A Multicenter Cohort Study Using the TriNetX Research Network
Hsin-Hua Chen, Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)

Background/Purpose: Belimumab and anifrolumab, biologic therapies, have shown to improve systemic lupus erythematosus (SLE) outcomes in clinical trials, but there is a lack of real-world…
Abstract Number: 1903 • ACR Convergence 2024
Impact of Multimorbidity on Targeted Synthetic and Biologic Disease-modifying Antirheumatic Drug (ts/bDMARD) Effectiveness in Patients with Rheumatoid Arthritis: A Two Year Follow-up Study from Mexican Adverse Events Registry BIOADAMEX
Vijaya Rivera Teran¹, David Vega Morales², Iris Jazmín Colunga Pedraza³, Sandra Sicsik Ayala⁴, Angel Alejandro Castillo Ortiz⁵, Miguel Angel Saavedra Salinas⁶, Dafhne Miranda Hernández⁷, Fedra Irazoque Palazuelos⁸, Julio César Casasola Vargas⁹, Omar Eloy Muñoz Monroy¹⁰, Sandra Carrillo Vazquez⁸, javier Merayo Chalico¹¹, Guillermo Guaracha Basañez¹², Estefania Torres Valdez¹³, Luis Valdés Corona¹⁴, Angélica Peña Ayala¹⁵, Sergio Durán Barragán¹⁶, Azucena Ramos Sánchez², Aleni Paz Viscarra¹⁴, Erick Adrián Zamora Tehozol¹⁷, Daniel Xibillé Friedman¹⁸ and Jiram Torres Ruiz¹⁹, ¹Colegio Mexicano de Reumatología, Mexico City, Mexico, ²Instituto Mexicano del Seguro Social, Monterrey, Mexico, ³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Instituto Mexicano del Seguro Social, Torreón, Mexico, ⁵Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Merida, Mexico, ⁶División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, ⁷Instituto Mexicano del Seguro Social, Mexico City, Mexico, ⁸Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City, Mexico, ⁹Hospital General de México, “Dr.Eduardo Liceaga”, MEXICO CITY, Mexico, ¹⁰Hospital Central Militar, Mexico City, Mexico, ¹¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, CDMX, Mexico, ¹²Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirón", Mexico City, Mexico, ¹³Instituto Mexicano del Seguro Social, Querétaro, Mexico, ¹⁴Práctica Privada, Mexico City, Mexico, ¹⁵Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Ciudad de Mexico, Distrito Federal, Mexico, ¹⁶Clínica de Investigación en Reumatología, Guadalajara, Mexico, ¹⁷Práctica Privada, Merida, Mexico, ¹⁸Práctica Privada, Cuernavaca, Mexico, ¹⁹INCMNSZ, Mexico, Federal District, Mexico
Background/Purpose: To evaluate the impact of multimorbidity on the effectiveness of targeted synthetic and biologic disease-modifying antirheumatic drug (ts/bDMARD), in patients with rheumatoid arthritis in a two-year follow-up.Methods:…
Abstract Number: 2177 • ACR Convergence 2024
CD59 Complement Membrane Regulator Deficiency: 12 Years of Clinical and Molecular Follow-up of 29 Patients
Dror Mevorach, Netanel Karbian, Marian Zeibak and Adi Tabib, Hadassah-University Hospital, Jerusalem, Israel
Background/Purpose: We have described in 2013, homozygous CD59-deficient children that manifest with recurrent peripheral neuropathy resembling Guillain-Barré syndrome (GBS), with hemolytic anemia and recurrent strokes.…
Abstract Number: 2402 • ACR Convergence 2024
Belimumab Reduces Disease Flares versus Placebo in Adults with Early Active Systemic Lupus Erythematosus: Results of a Large Integrated Analysis
Marta Mosca¹, Karen Costenbader², Joan Merrill³, Holly Quasny⁴, Christine Henning⁵, Steven Bloom⁶, Julia Harris⁶, Ciara O’Shea⁷, Tatsuya Atsumi⁸ and Ronald Van Vollenhoven⁹, ¹University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ²Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ³Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, ⁴GSK, Clinical Sciences, Durham, NC, ⁵GSK, Global Medical Affairs, Durham, NC, ⁶GSK, Immunology Biostatistics, Brentford, United Kingdom, ⁷GSK, Rheumatology, Global Medical Affairs, Dublin, Ireland, ⁸Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ⁹Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: SLE flares are associated with increased risk of organ damage/mortality; flare prevention is a key treatment goal.1 Initiating treatment earlier has benefits in autoimmune…
Abstract Number: 2619 • ACR Convergence 2024
Safety Outcomes of Routine Blood Tests for Monitoring of Biologic and Targeted Synthetic Therapies in Inflammatory Arthritis Patients
Tali Eviatar¹, Iftach Sagy², Elad Brav², Amir Bieber³, Victoria Furer⁴ and Ori Elkayam⁵, ¹Tel Aviv Medical Center, Ramat Gan, HaMerkaz, Israel, ²Soroka Medical Cenrter, beer sheva, Israel, ³Emek Medical Center, Clalit Health Services, Raanana, Israel, ⁴Tel Aviv Medical Center, Tel Aviv, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Background/Purpose: Patients treated with biologic or targeted synthetic (b/ts) DMARDs are recommended to perform safety blood monitoring every 3 months in the absence of strong…
Abstract Number: 0249 • ACR Convergence 2024
Real World Evidence on the Safety of the Adjuvanted Recombinant Zoster Vaccine in Patients with Rheumatic Diseases – Preliminary Results from a Prospective Multicenter Observational Greek Study
Christos Koutsianas¹, Anastasia Apanomeritaki², Evgenia Mavrea¹, Niki-Violeta Dimopoulou¹, Maria Nitsa¹, CHRISTINA TSALAPAKI¹, Iro-Ioanna Giannakopoulou² and Dimitrios Vassilopoulos¹, ¹Clinical Immunology-Rheumatology Unit, 2nd Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece, ²Rheumatology Clinic, General Hospital Asklepieio Voulas, Voula, Attiki, Greece
Background/Purpose: Patients with rheumatic diseases (RD) are at increased risk for herpes zoster (HZ) due to disease -related aberrant immune response, comorbid conditions and anti-rheumatic…
Abstract Number: 0504 • ACR Convergence 2024
Janus Kinase Inhibitors Persist Longer Than Biologics in Rheumatoid Arthritis: Retrospective Analysis of Real-world Outpatient Data from the German Rhadar Database
Linus Maximilian Risser¹, Torsten Witte², Matthias Englbrecht³, Patrick-Pascal Strunz⁴, Matthias Froehlich⁵, Marc Schmalzing⁶, Michael Gernert⁷, Peter Bartz-Bazzanella⁸, Cay von Der Decken⁹, Kirsten Karberg¹⁰, Georg Gauler¹¹, Susanna Spaethling-Mestekemper¹², Christoph Kuhn¹³, Wolfgang Vorbrueggen¹⁴, Martin Welcker¹⁵ and Stefan Kleinert¹⁶, ¹Hannover Medical School, Hannover, Germany, ²Dept of Immunology and Rheumatology, Hannover, Germany, ³Freelance Healthcare Data Scientist, Eckental, ⁴University hospital of Wuerzburg, Wuerzburg, Germany, ⁵Uniklinikum Wuerzburg, Medizinische Klinik II, Wuerzburg, Germany, ⁶University Hospital Wuerzburg, Würzburg, Germany, ⁷Medicine II, Division Rheumatology/Clinical Immunology, University Hospital of Wuerzburg, Wuerzburg, ⁸Rhein-Maas Klinikum, Wuerselen, Germany, ⁹Klinik für Internistische Rheumatologie, Rhein-Maas-Klinik Wuerselen, Würselen, ¹⁰Rheumatologisches Versorgungszentrum Steglitz, Berlin, Germany, ¹¹rheumapraxis, Osnabrück, Germany, ¹²Rheumapraxis Muenchen, Muenchen, Germany, ¹³Praxis für Rheumatologie, Karlsruhe, Germany, ¹⁴Verein zur Foerderung der Rheumatologie e.V, Wuerselen, Germany, ¹⁵Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, ¹⁶Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany
Background/Purpose: Numerous biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have been approved for treating rheumatoid arthritis (RA), including Janus kinase inhibitors (JAKi), rituximab, abatacept,…
Abstract Number: 0585 • ACR Convergence 2024
Cycling to TNFi vs. Switching to IL-17Ai After a First TNFi Discontinuation Among Patients with PsA and axSpA: The CorEvitas PsA/SpA Registry
Alexis Ogdie¹, Nicole Middaugh², Maya Marchese², Jessica A Walsh³, Natalia Bello⁴, Jeffrey Lisse⁴, Andris Kronbergs⁵, Elsie Grace⁶, Marcus Ngantcha⁴ and Philip Mease⁷, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly, Indianapolis, IN, ⁶Eli Lilly and Company, Indianapolis, ⁷Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Treatment guidelines recommend tumor necrosis factor inhibitors (TNFi) and interleukin-17A inhibitors (IL-17Ai) as options for patients with PsA or axSpA with persistent disease activity…
Abstract Number: 0765 • ACR Convergence 2024
Tocilizumab in Extracranial Large-Vessel Giant Cell Arteritis and Takayasu Arteritis: A Multicentric Observational Comparative Study
Carmen Lasa Teja¹, Javier Loricera², Diana Prieto-Peña³, fernando lopez gutierrez⁴, Pilar Bernabéu⁵, Mercedes Freire González⁶, ivan Ferraz-Amaro⁷, Santos Castañeda⁸, Mauricio Mínguez⁹, Beatriz bravo-Mancheño¹⁰, Roser Solans-Laqué¹¹ and Ricardo Blanco-Alonso¹², ¹Hospital Universitario Marqués de Valdecilla, Riotuerto, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ⁴Rheumatology, madrid, Madrid, Spain, ⁵Rheumatology section, Dr. Balmis General University Hospital-ISABIAL, Alicante, Spain, Alicante, Spain, ⁶Complexo Hospitalario Universitario de A Coruña, La coruna, Galicia, Spain, ⁷Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Hospital San Juan de Alicante, Rheumatology., Alicante, Spain, ¹⁰Hospital Universitario Virgen de las Nieves, Granada, Granada., Spain, ¹¹Internal Medicine Service, Vall d'Hebron Hospital University and Campus, Barcelona, Spain, ¹²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Tocilizumab (TCZ) seems to be effective in large vessel (LV) vasculitis including giant cell arteritis (GCA) and Takayasu arteritis (TAK). LV-GCA phenotype shares some…
Abstract Number: 1049 • ACR Convergence 2024
Very Low Uptake of Biosimilar Adalimumab in the First 9 Months of Availability in Rheumatology
Eric Roberts¹, Gabriela Schmajuk² and Jinoos Yazdany³, ¹University of California, San Francisco, SF, CA, ²UCSF / SFVA, San Francisco, CA, ³UCSF, San Francisco, CA
Background/Purpose: In 2021, over 300,000 patients in the United States used adalimumab, making it one of the highest-grossing drugs globally. In 2023, patent exclusivity for…
Abstract Number: 1401 • ACR Convergence 2024
Risk of Malignancy with TNF-α Inhibitors in Patients with Rheumatoid Arthritis
Omair Khan¹, Syed Mujtaba Baqir², Azka Naeem², Muhammad Hashim khan², Tharun Shyam², Kseniya Slobodyanyuk³ and Anastasia Slobodnick⁴, ¹Maimonides Medical Center, Council Bluffs, IA, ²Maimonides Medical Center, Brooklyn, NY, ³Maimonides Medical Center, Manhattan, NY, ⁴Northwell, Staten Island, NY
Background/Purpose: Rheumatoid arthritis (RA) is associated with various comorbidities and complications among which cancer has been highlighted in literature. This cancer risk has been attributed…
Abstract Number: 1530 • ACR Convergence 2024
Belimumab-Treated Patients with Systemic Lupus Erythematosus Without Prior Immunosuppressant Use Have More Favorable Clinical Outcomes Than Those with Prior Use of an Immunosuppressant
Maral DerSarkissian¹, Yan Chen¹, Brendan Rabideau¹, Theo Man¹, Karen Worley², Bernard Rubin³, Karen Costenbader⁴ and S. Sam Lim⁵, ¹Analysis Group, Los Angeles, CA, ²GSK, Collegeville, PA, ³GSK, Durham, NC, ⁴Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁵Emory University, Atlanta, GA

Background/Purpose: Early diagnosis and treatment of SLE improves prognosis and quality of life.1 Belimumab (BEL), a human immunoglobulin G1λ (IgG1λ) mAb that selectively binds to…
Abstract Number: 1978.5 • ACR Convergence 2024
Post-Hoc Analysis of Clinically Relevant Anti-Vaccine Antibodies in Participants with Rheumatoid Arthritis Treated with Nipocalimab
Faye Yu¹, Eugene Myshkin², Carolina Bobadilla Mendez³, Marta Cossu⁴, Kaiyin Fei⁵, Qingmin Wang⁶, Matthew J. Loza⁶, Dessislava Dimitrova³ and Sheng Gao³, ¹Janssen Research & Development, LLC, a Johnson & Johnson company, Cambridge, MA, USA, MA, MA, ²Janssen Research & Development, LLC, a Johnson & Johnson company, Cambridge, MA, ³Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, ⁴Janssen Pharmaceutical Research and Development, a Johnson & Johnson company, Leiden, Netherlands, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, USA, Spring House, PA

Background/Purpose: Nipocalimab is a fully human, high affinity, aglycosylated, effectorless IgG1 monoclonal antibody designed to selectively block neonatal fragment crystallizable receptor (FcRn), thereby lowering IgG…
Abstract Number: 2225 • ACR Convergence 2024
Role of Fatigue in Difficult to Treat Rheumatoid Arthritis
Maria Rodriguez-Laguna¹, Leticia Leon², Dalifer Freites Nuñez³, Cristina Hormigos-martin⁴, jose otazu Moudelle⁴, Alfredo Madrid García⁵, Benjamin fernandez-Gutierrez² and lydia Abasolo Alcazar⁶, ¹Resident in Rheumatology, Madrid, Spain, ²Hospital Clinico San Carlos, Madrid, Spain, ³Hospital Clínico San Carlos. Madrid. Spain., Madrid, Spain, ⁴Hospital Clínico San Carlos, madrid, Spain, ⁵Fundación para la Investigación Biomédica del Hospital Clínico San Carlos (IDISCC), Madrid, Madrid, Spain, ⁶IdISSC. HCSC, Madrid, Spain
Background/Purpose: A subset of patients with rheumatoid arthritis (RA) who remains symptomatic after failing to multiple therapies are deemed to have "difficult-to-treat" (D2T RA). Fatigue…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].